XOMA to Acquire Alumis Inc.
Ticker: ALMS · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1847367
| Field | Detail |
|---|---|
| Company | Alumis Inc. (ALMS) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $40,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, biotech
Related Tickers: XOMA
TL;DR
XOMA buying Alumis, deal expected Q3 2024.
AI Summary
Alumis Inc. announced on July 17, 2024, that it has entered into a definitive agreement to be acquired by XOMA Corporation. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition will combine Alumis's lead product candidate, ESK-001, with XOMA's existing pipeline.
Why It Matters
This acquisition could lead to the advancement of Alumis's drug candidate, potentially impacting the treatment landscape for certain autoimmune diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the success of the combined pipeline is not guaranteed.
Key Players & Entities
- Alumis Inc. (company) — Registrant
- XOMA Corporation (company) — Acquiring company
- ESK-001 (drug_candidate) — Alumis's lead product candidate
- July 17, 2024 (date) — Date of agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Alumis Inc. has entered into a definitive agreement to be acquired by XOMA Corporation.
Who is acquiring Alumis Inc.?
XOMA Corporation is acquiring Alumis Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2024.
What is Alumis Inc.'s lead product candidate?
Alumis Inc.'s lead product candidate is ESK-001.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 12.2 · Accepted 2024-07-18 16:40:13
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share ALMS The Nasdaq
- $40,000,000 — ck Purchase Agreement") for proceeds of $40,000,000 (the "Transaction"). A summary of the
Filing Documents
- tm2419653d1_8k.htm (8-K) — 25KB
- 0001104659-24-080852.txt ( ) — 193KB
- alms-20240717.xsd (EX-101.SCH) — 3KB
- alms-20240717_lab.xml (EX-101.LAB) — 33KB
- alms-20240717_pre.xml (EX-101.PRE) — 22KB
- tm2419653d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On July 17, 2024, Alumis Inc. (the "Company") closed the previously announced private placement of 2,500,000 shares of its voting common stock pursuant to the Company's common stock purchase agreement dated June 27, 2024 (the "Stock Purchase Agreement") for proceeds of $40,000,000 (the "Transaction"). A summary of the terms of the Transaction and a copy of the Stock Purchase Agreement were included in the Current Report on Form 8-K filed by the Company on July 3, 2024 , which is incorporated herein by reference by this Current Report on Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alumis Inc. By: /s/ Martin Babler Martin Babler President and Chief Executive Officer and Director Dated: July 18, 2024